Brunel University Research Archive (BURA) >
School of Health Sciences and Social Care >
School of Health Sciences and Social Care Research Papers >
Please use this identifier to cite or link to this item:
|Title: ||Economic evaluation of ASCOT-BPLA: Antihypertensive treatment with an amlodipine-based regimen is cost-effective compared to an atenolol-based regimen|
|Authors: ||Lindgren, P|
|Publication Date: ||2007|
|Publisher: ||British Medical Journals Publishing Group Ltd & British Cardiovascular Society|
|Citation: ||Heart, 94(2): e4, 4th October 2007|
|Abstract: ||Objective: To compare the cost effectiveness of an amlodipine-based strategy and an atenolol-based strategy in the treatment of hypertension in the UK and Sweden.
Design: A prospective, randomised trial complemented with a Markov model to assess long-term costs and health effects.
Setting: Primary care.
Patients: Patients with moderate hypertension and three or more additional risk factors.
Interventions: Amlodipine 5–10 mg with perindopril 4–8 mg added as needed or atenolol 50–100 mg with bendroflumethiazide 1.25–2.5 mg and potassium added as needed
Main outcome measures: Cost per cardiovascular event and procedure avoided, and cost per quality-adjusted life-year gained.
Results: In the UK, the cost to avoid one cardiovascular event or procedure would be €18 965, and the cost to gain one quality-adjusted life-year would be €21 875. The corresponding figures for Sweden were €13 210 and €16 856.
Conclusions: Compared with the thresholds applied by NICE and in the Swedish National Board of Health and Welfare’s Guidelines for Cardiac Care, an amlodipine-based regimen is cost effective for the treatment of hypertension compared with an atenolol-based regimen in the population studied.|
|Description: ||Copyright © 2010 BMJ Publishing Group Ltd & British Cardiovascular Society. Internal or personal use of this material is permitted. However, permission to reprint/republish this material must be obtained from the Publisher.|
|Sponsorship: ||The study was supported by the principal funding source, Pfizer, New York, USA.|
|Appears in Collections:||School of Health Sciences and Social Care Research Papers|
Community Health and Public Health
Health Economics Research Group (HERG)
Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.